ClinicaliQ Trial Snapshot
- Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) — Active Not Recruiting • Phase III • Gastroenterology • NCT04526665.
- Elafibranor tested against placebo in PBC patients inadequately responding to ursodeoxycholic acid, assessing alkaline phosphatase reduction and safety.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease). PBC is a slowly progressive disease characterized by damage of the bile ducts in the liver, leading to a buildup of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die…